Please select the option that best describes you:
Topics:
Radiation Oncology • ASTRO 2025
How do you account for dosimetric contributions from 177Lu-PNT2002 when planning SBRT?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Clinical Trials Session Presentation "177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial" by Dr. Amar Kishan.
Answer from: Radiation Oncologist at Academic Institution
This is challenging and will be a timely question. In this specific trial, we did perform timed SPECT/CT scans after 177Lu-PNT2002 to try to compute dose to various OARs (and tumor). It is difficult to model this, but there are some published references that allow one to estimate the dose contributi...
Sign in or Register to read more